gsk201502176k.htm
FORM 6-K/A
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

athe Securities Exchange Act of 1934
 
 
 
For period ending February 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--


Notification of Transactions of
Directors and Persons Discharging Managerial Responsibility
 
Vesting of Dividend Shares attaching to Conditional Share Awards
 
This notification sets out information relating to the vesting of conditional share awards under the GlaxoSmithKline 2009 Performance Share Plan (the "Performance Share Plan") and the 2009 Deferred Annual Bonus Plan (the "Deferred Annual Bonus Plan").
 
This announcement covers the vesting of shares from dividends related to the awards made to Corporate Executive Team members and to senior executives who have subsequently been designated as Persons Discharging Managerial Responsibility in 2012, which awards were the subject of a vesting announcement on 13 February. It was indicated in that announcement that the dividend shares would be announced once the final number of dividend shares had been notified to the Company.
 
2012 Performance Share Plan Award Dividend Shares
 
As previously announced, 13.5% of the 2012 Performance Share Plan awards vested.
 
The table below shows the proportion of the dividend shares associated with the 2012 Performance Share Plan awards that vested and lapsed on 12 February 2015:
 
 
Dividend shares which have vested
Dividend shares which have lapsed
Ordinary Shares
ADS
Ordinary Shares
ADS
Sir Andrew Witty*
9,990
 
63,989
 
Mr S Dingemans*
3,846
 
24,636
 
Dr M Slaoui*
 
2,933
 
18,788
Ms D Connelly
 
1,215
 
7,781
Mr A Hussain
2,514
 
16,099
 
Mr W Louv
 
862
 
5,510
Mr D Redfern
1,441
 
9,229
 
Ms C Thomas
1,889
 
12,101
 
Mr P Thomson
962
 
6,151
 
Mr D Troy
 
1,595
 
10,212
Mr P Vallance
3,682
 
23,586
 
Ms E Walmsley
2,177
 
13,947
 
* denotes an Executive Director
**25% of Sir Andrew Witty's vested shares (i.e., 14,915 ordinary shares) will be held back, "the holding tranche", for an additional two years as agreed with shareholders beginning with his 2012 Performance Share Plan award. The same treatment will also be applied to the equivalent proportion of the above dividend shares which have vested.
 
2012 Deferred Annual Bonus Awards
 
The table below shows the dividend shares that relate to the pre tax Deferred Awards that will vest on the third anniversary of grant, 9 March 2015.
 
 
Nil Cost Option over Ordinary Shares (Deferred Bonus Awards): Dividend Shares
Conditional Awards of ADSs (Deferred Bonus Awards): Dividend Shares
Vested
Vested
Sir Andrew Witty*
8,357
 
Mr S Dingemans*
4,934
 
Dr M Slaoui*
 
3,290
Ms D Connelly
 
961
Mr W Louv
 
832
Mr D Redfern
2,108
 
Ms C Thomas
2,590
 
Mr D Troy
 
1,726
Mr P Vallance
3,590
 
Ms E Walmsley
1,789
 
* Denotes an Executive Director
 
The table below shows the dividend shares that relate to the post tax Deferred Award that will vest on the third anniversary of grant, 12 March 2015.
 
 
Co-Investment Shares ADSs: Dividend Shares
Released
Ms D Connelly
182
 
As announced on 13 February and noted above, for the three year period 1 January 2012 to 31 December 2014, the Remuneration Committee has confirmed that 13.5% of the award of Matching Shares will vest based on performance and that the balance lapsed. The table below shows the dividend shares relating to the pre tax Matching Awards that will vest on 9 March 2015, the third anniversary of the Award.
 
 
Nil Cost Option over Ordinary Shares (Matching Shares): Dividend Shares
Conditional Awards over ADSs (Matching Shares): Dividend Shares
Vested
Lapsed
Vested
Lapsed
Sir Andrew Witty*
1,128
7,229
   
Mr S Dingemans*
666
4,268
   
Dr M Slaoui*
   
445
2,845
Ms D Connelly
   
130
831
Mr W Louv
   
113
719
Mr D Redfern
285
1,823
   
Ms C Thomas
351
2,239
   
Mr D Troy
   
234
1,492
Mr P Vallance
485
3,105
   
Ms E Walmsley
242
1,547
   
* Denotes an Executive Director
 
The above nil cost options in respect of Deferred Shares and Matching Shares can be exercised until 9 March 2022. Dividends no longer accrue on these shares following vesting.
 
The table below shows the dividend shares relating to the post tax Matching Shares that will vest on 12 March 2015, the third anniversary of the Award:
 
 
Conditional Awards over ADSs: Dividend Shares
Vested
Lapsed
Ms D Connelly
26
159
 
2012 Performance Share Plan Award Dividend Shares for senior executives who have since been designated PDMRs
 
The table below shows the proportion of the dividend shares related to the 2012 Performance Share Plan conditional awards that vested and lapsed on 12 February 2015 per the previous Friday, 13 February announcement.
 
 
Dividend shares which have vested
Dividend shares which have lapsed
Ordinary Shares
Ordinary Shares
Mr R Connor
0
2,709
Mrs V Whyte
0
1,975
     
ADSs
ADSs
Mr N Hirons
0
1,129
 
The Company, Executive Directors and PDMRs were advised of these transactions on 16 February 2015.
 
The closing share prices of an Ordinary Share and of an ADS of GlaxoSmithKline plc at the point of vesting on 12 February 2015 were £14.855 and US$45.95 respectively.
 
This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
VA Whyte
Company Secretary
 
17 February 2015
 
                                                                                

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: February 17, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc